Observational studyClinical rheumatology2026
Evaluation of predictors and clinical outcome after tapering of chronic systemic corticosteroids in Behçet's disease patients.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify predictive factors for successful oral glucocorticoid (GC) tapering in a longitudinal cohort of Behçet's disease (BD) patients in remission or with low disease activity, and to evaluate post-tapering outcomes over a one-year period.
methodsThis is an observational longitudinal cohort study, focusing on BD patients who began GC tapering and achieved remission or low disease activity. Patients who achieved sustained remission or low disease activity while maintaining a prednisone dose of ≤ 5 mg/day were classified as "successful tapering," while those who failed to achieve this outcome were classified as "failed tapering". A regression model was used to identify predictors of successful GC tapering to ≤ 5 mg/day.
resultsA total of 72 BD patients were enrolled and followed-up for 12 months. Multivariate analysis confirmed that short disease duration (odds ratio (OR) = 0.395, 95% CI: 0.197-0.794, p = 0.009), low activity at disease onset (OR = 0.177, 95% CI: 0. 037-0.846, p = 0.03), low severity score for BD at baseline (OR = 0.092, 95% CI:.010-0.876, p = 0.038), and low C-reactive protein value at baseline (OR = 0.186, 95% CI:0.039-0.883, p = 0.034) were the predictors for successful GC tapering.
conclusionThe independent factors linked to success in tapering glucocorticoid in BD were shorter disease duration, low activity at disease onset, low severity score at baseline, and low C-reactive protein value. These findings suggest that they could be used in clinical settings to identify tapering candidates. Key Points •1- Behcet disease is a challenge to treat and usually necessitates a multidisciplinary strategy •2- Glucocorticoids have been used to treat almost all disease lesions •3- Long-term Glucocorticoids use is associated with adverse events •4- The independent factors linked to success in tapering glucocorticoid in Behcet disease were short disease duration, low activity at disease onset, low severity score at baseline, and low C-reactive protein value.
Indexed as
Identifiers
41191245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.